Title : Sustained treatment with an α5 GABA A receptor negative allosteric modulator delays excitatory circuit development while maintaining GABAergic neurotransmission.

Pub. Date : 2021 Oct 1

PMID : 34284042






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In contrast, alpha5-NAM treatment from DIV19-21, when hyperpolarizing GABAAR signaling predominates, enhances surface synaptic GluN2A while decreasing GluN2B. alpha5-nam gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus
2 Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines. alpha5-nam gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus
3 Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines. alpha5-nam gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus
4 Furthermore, alpha5-NAM inhibition of the GABAAR tonic current in mature neurons is maintained after 2-day alpha5-NAM treatment, suggesting reduced tolerance liability, in contrast to other clinically relevant GABAAR-targeting drugs such as benzodiazepines. Benzodiazepines gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus